Twin Tree Management
APLS

Twin Tree Management’s Apellis Pharmaceuticals APLS Stock Holding History

Twin Tree Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,200
Closed -$1.38M – 1216
2023
Q2 		$1.38M Sell
15,200
-123,000
-89% -$10.6M ﹤0.01% 964
2023
Q1 		$9.12M Buy
+138,200
New +$7.97M 0.02% 598

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Twin Tree Management's APLS Position: Q1 2019 in Review

Twin Tree Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2019, closing a stake of 263 shares — an estimated $3K sold.

Twin Tree Management first reported a position in APLS in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 92 funds tracked by Wall St. Rank hold APLS as of Q1 2019.

  • Twin Tree Management reported no remaining Apellis Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Twin Tree Management sold 263 Apellis Pharmaceuticals shares in Q1 2019, an estimated $3K.
  • Twin Tree Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Twin Tree Management's Apellis Pharmaceuticals position peaked at $3K in Q4 2018.
  • 92 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2019.

Based on Twin Tree Management's 13F filing for Q1 2019, filed 10 May 2019.